



Infomerics Valuation And Rating Pvt. Ltd.

Press Release

Navkar Lifesciences

March 04, 2020

Ratings

Sl. No.	Instrument/Facility	Amount (Rs. Crore)	Ratings Assigned
1	Bank Facilities- Long Term	19.75	IVR BB-/Stable Outlook (IVR Double B Minus with Stable Outlook)
2.	Bank Facilities- Short Term	2.70	IVR A4 (IVR A four)
	Total	22.45	

Details of Facilities are in Annexure 1

Detailed Rationale

The ratings assigned to the bank facilities of Navkar Lifesciences (NL) derives comfort from its experienced partners, long track record in pharmaceutical industry with diversified client base, synergies derived from group concerns, locational advantage, moderate capital structure with debt protection metrics. The rating strengths are partially offset by its small scale of operations, moderate debt protection metrics, working Capital intensive operations, and inherent risk available in the constitution of partnership firm.

Key Rating Sensitivities

Upward factors

Sharp increase in scale of operation with improvement in profitability on a sustained basis

Improvement in the net worth base and capital structure

Improvement in operating cycle and improvement in liquidity with reduction in working capital limits utilisation to below 90%.

Downward factors

Moderation in total income and/or profitability affecting the debt protection metrics and/or liquidity

Deterioration in the capital structure

Elongation in operating cycle



Infomerics Valuation And Rating Pvt. Ltd.

List of Key Rating Drivers with Detailed Description

Key Rating Strengths

Experienced partners

Mr. Abhay Jain and Mr. Ravi Jain are the partners of the firm and carrying over a decade of experience in the industry. Also, the firm is getting benefit from their experience and long standing relationship with their customers and suppliers which reduces the counterparty default risk as well as helps to enjoys extended credit period from its suppliers.

Long track record in pharmaceutical industry with diversified client base

The firm has about one and half decade-long track record of operations in the pharmaceutical industry. NL's revenues are diversified across revenues from owned brand sales, contract manufacturing and tender-based business. Over the years, NL has built an established client base in the contract manufacturing segment, while it distributes its own products through a network. NL has a diversified client base, it serves to the large client base reflected in the top 10 customers amounting to Rs.13.01 crore, which constitutes ~16.% of total sales in FY19.

Synergies derived from group concerns

The firm has more than 50 products in its product profile and caters to a broad range of segments like analgesic, nutritional, dermatological, anti-allergic, anti-diabetic, anti-fungal, and anti-depressant. Having a wide product portfolio helped the firm to have a diversified customer base. Further, its group entity, Arion Healthcare is also in the same line of business. Presence of group concern in the same field provides synergy benefits. Further, the partners also has a packaging manufacturing entity which further lends some synergies.

Locational Advantage

Its plant is located in Baddi, Himachal Pradesh which is in proximity to its principals and suppliers and provides competitive advantage.

Moderate capital structure and debt protection metrics

The debt profile of the firm mainly comprised of working capital borrowings due to its working capital intensive nature of operations consequently the overall gearing ratio stood moderate at 1.32x as on March 31, 2019. Further, total indebtedness of the firm as reflected by TOL/TNW



Infomerics Valuation And Rating Pvt. Ltd.

also stood moderate at 2.23x as on March 31, 2019 (against 2.00x as on March 31, 2018). The debt protection metrics of the firm remained moderate with an interest coverage at 1.74x and total debt to GCA at 9.84 years in FY19.

Key Weaknesses

Small scale of operations with weak profitability

The total operating income of the firm though witnessed a muted growth at a CAGR of ~4% and witnessed a y-o-y growth of ~5% remained small over the past three years during FY17-FY19. Small scale of operations limits the economics of scale benefits and pricing flexibility. Further, the operating profit margin of the firm remained erratic over the past three years and the PAT margin witnessed a declining trend during the aforesaid period. In FY19, the EBITDA margin stood moderate at 7.02% and the PAT margin stood thin at 1.03%. During 9MFY20, the firm has achieved a total operating income of Rs.64.05 crore.

Working capital intensive nature of operations

NL's operations are working capital intensive due to its long collection period and high inventory holding period consequently, the operating cycle of the firm remained elongated at 124 day in FY19. Further, the funds are blocked in GST for inverted rates which also affected the liquidity. To fund its working capital requirements the firm is largely dependent on bank borrowings and consequently it has a high working capital limit utilisation at ~98% in the past 12 months ended September, 2019. The firm's ability to manage further growth funding remains crucial for maintaining a comfortable liquidity position.

Inherent risk available in the constitution of partnership firm

Being a partnership firm, NL is exposed to inherent risk of withdrawal of capital and less regulatory compliances.

Analytical Approach: Standalone



Infomerics Valuation And Rating Pvt. Ltd.

Applicable Criteria:

Rating Methodology for Manufacturing Companies

Financial Ratios & Interpretation (Non-financial Sector)

Liquidity: Stretched

Liquidity is stretched marked by its highly utilized bank limits due to high working capital intensity in the business. The average cash credit utilization for the past twelve months ended on Sep, 2019 remained high around 98% indicating a limited liquidity cushion. Enhancement in bank limit is critical from liquidity perspective.

About the Firm

Navkar Lifesciences (NL) established in 2016, located in Baddi, Himachal Pradesh is engaged in manufacturing, distributing and supplying medicines for various purposes. Its product range includes Pharmaceutical Tablets, General Health Tablets, Vitamin B Complex Syrup, Eye Drops, Liver Tonic and many more. The partners have another entity engaged in same line of business namely, Arion Healthcare.

Financials (Standalone):

(Rs. crore)

For the year ended*	31-03-2018	31-03-2019
	Audited	Audited
Total Operating Income	76.11	79.97
EBITDA	6.20	5.61
PAT	1.82	1.26
Total Debt	23.79	23.68
Tangible Net worth	17.17	17.96
EBITDA Margin (%)	8.15	7.02
PAT Margin (%)	2.91	1.73
Overall Gearing Ratio (x)	1.39	1.32

*Classification as per Infomerics' standards

Status of non-cooperation with previous CRA: Nil

Any other information: Nil.



Infomerics Valuation And Rating Pvt. Ltd.

Rating History for last three years:

Sr. No.	Name of Instrument/ Facilities	Current Rating (Year 2019-20)			Rating History for the past 3 years		
		Type	Amount outstanding (Rs. Crore)	Rating	Date(s) & Rating(s) assigned in 2018-19	Date(s) & Rating(s) assigned in 2017-18	Date(s) & Rating(s) assigned in 2016-17
1.	Cash Credit	Long Term	19.75	IVR BB- /Stable	-	-	-
2.	Bank Guarantee	Short Term	2.70	IVR A4	-	-	-

Note on complexity levels of the rated instrument: Infomerics has classified instruments rated by it on the basis of complexity and a note thereon is available at www.infomerics.com.

Name and Contact Details of the Rating Analyst:

Name: Mr. Ravi Malik Tel: (011) 24655636 Email: rmalik@infomerics.com	Name: Mr. Avik Podder Tel: (033) 46022266 Email: apodder@infomerics.com
--	---

About Infomerics:

Infomerics commenced rating & grading operations in April 2015 after having spent over 25 years in various segments of financial services. Infomerics is registered with the Securities and Exchange Board of India (SEBI) and accredited by Reserve Bank of India. It is gradually gaining prominence in domestic rating and/or grading space. Infomerics is striving for positioning itself as the most trusted & credible rating agency in the country and is gradually widening its product portfolio. Company's long experience in varied spectrum of financial services is helping it to fine tune its product offerings to best suit the market.



Infomerics Valuation And Rating Pvt. Ltd.

Disclaimer: Infomerics ratings are based on information provided by the issuer on an 'as is where is' basis. Infomerics credit ratings are an opinion on the credit risk of the issue / issuer and not a recommendation to buy, hold or sell securities. Infomerics reserves the right to change, suspend or withdraw the credit ratings at any point in time. Infomerics ratings are opinions on financial statements based on information provided by the management and information obtained from sources believed by it to be accurate and reliable. The credit quality ratings are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. We, however, do not guarantee the accuracy, adequacy or completeness of any information which we accepted and presumed to be free from misstatement, whether due to error or fraud. We are not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by us have paid a credit rating fee, based on the amount and type of bank facilities/instruments. In case of partnership/proprietary concerns/Association of Persons (AOPs), the rating assigned by Infomerics is based on the capital deployed by the partners/proprietor/ AOPs and the financial strength of the firm at present. The rating may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor/ AOPs in addition to the financial performance and other relevant factors.

Annexure 1: Details of Facilities

Name of Facility	Date of Issuance	Coupon Rate/ IRR	Maturity Date	Size of Facility (Rs. Crore)	Rating Assigned/ Outlook
Long Term Bank Facilities- Cash Credit	-	-	-	19.75	IVR BB- /Stable
Short Term Bank Facilities- Bank Guarantee	-	-	-	2.70	IVR A4